MXPA99000074A - A method for treating liver diseases and similar indications with vasodilated agents - Google Patents
A method for treating liver diseases and similar indications with vasodilated agentsInfo
- Publication number
- MXPA99000074A MXPA99000074A MXPA/A/1999/000074A MX9900074A MXPA99000074A MX PA99000074 A MXPA99000074 A MX PA99000074A MX 9900074 A MX9900074 A MX 9900074A MX PA99000074 A MXPA99000074 A MX PA99000074A
- Authority
- MX
- Mexico
- Prior art keywords
- liver
- derivative
- composition according
- composition
- group
- Prior art date
Links
- 201000009673 liver disease Diseases 0.000 title claims abstract description 39
- 210000004185 Liver Anatomy 0.000 claims abstract description 54
- 239000003071 vasodilator agent Substances 0.000 claims abstract description 18
- 201000010099 disease Diseases 0.000 claims abstract description 15
- 239000003814 drug Substances 0.000 claims abstract description 15
- 210000004369 Blood Anatomy 0.000 claims abstract description 13
- 239000008280 blood Substances 0.000 claims abstract description 13
- 229940079593 drugs Drugs 0.000 claims abstract description 13
- 208000006454 Hepatitis Diseases 0.000 claims abstract description 11
- 230000001965 increased Effects 0.000 claims abstract description 11
- 201000004044 liver cirrhosis Diseases 0.000 claims abstract description 11
- 230000002440 hepatic Effects 0.000 claims abstract description 6
- 231100000283 hepatitis Toxicity 0.000 claims abstract description 6
- 230000002588 toxic Effects 0.000 claims abstract description 5
- 231100000331 toxic Toxicity 0.000 claims abstract description 5
- 206010067125 Liver injury Diseases 0.000 claims abstract description 4
- 231100000234 hepatic damage Toxicity 0.000 claims abstract description 4
- 230000000261 vasodilator Effects 0.000 claims abstract description 4
- 230000004941 influx Effects 0.000 claims abstract 2
- 239000000203 mixture Substances 0.000 claims description 33
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims description 12
- 125000000217 alkyl group Chemical group 0.000 claims description 11
- 238000007792 addition Methods 0.000 claims description 10
- 239000000480 calcium channel blocker Substances 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 9
- 125000005843 halogen group Chemical group 0.000 claims description 8
- 230000003000 nontoxic Effects 0.000 claims description 8
- 231100000252 nontoxic Toxicity 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 239000011780 sodium chloride Substances 0.000 claims description 8
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 7
- 239000011575 calcium Substances 0.000 claims description 7
- 229910052791 calcium Inorganic materials 0.000 claims description 7
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 5
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 4
- 239000005977 Ethylene Substances 0.000 claims description 4
- 229960003580 Felodipine Drugs 0.000 claims description 4
- RZTAMFZIAATZDJ-UHFFFAOYSA-N Felodipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-UHFFFAOYSA-N 0.000 claims description 4
- SGTNSNPWRIOYBX-UHFFFAOYSA-N Verapamil Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 claims description 4
- 125000002252 acyl group Chemical group 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 125000002947 alkylene group Chemical group 0.000 claims description 4
- 150000007657 benzothiazepines Chemical class 0.000 claims description 4
- 125000001589 carboacyl group Chemical group 0.000 claims description 4
- 125000004432 carbon atoms Chemical group C* 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- VGGSQFUCUMXWEO-UHFFFAOYSA-N ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 150000004912 thiazepines Chemical class 0.000 claims description 4
- 229960001722 verapamil Drugs 0.000 claims description 4
- 230000002459 sustained Effects 0.000 claims description 3
- 229960001597 Nifedipine Drugs 0.000 claims description 2
- HYIMSNHJOBLJNT-UHFFFAOYSA-N Nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 2
- DQFQCHIDRBIESA-UHFFFAOYSA-N Benzazepine Chemical compound N1C=CC=CC2=CC=CC=C12 DQFQCHIDRBIESA-UHFFFAOYSA-N 0.000 claims 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Incidol Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 claims 1
- 125000005036 alkoxyphenyl group Chemical group 0.000 claims 1
- 230000004872 arterial blood pressure Effects 0.000 claims 1
- 200000000011 liver disorder Diseases 0.000 claims 1
- NYERMPLPURRVGM-UHFFFAOYSA-N thiazepine Chemical group S1C=CC=CC=N1 NYERMPLPURRVGM-UHFFFAOYSA-N 0.000 claims 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N Diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 42
- 229960004166 diltiazem Drugs 0.000 description 40
- 241000282472 Canis lupus familiaris Species 0.000 description 16
- VZGDMQKNWNREIO-UHFFFAOYSA-N Carbon tetrachloride Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 13
- 230000004044 response Effects 0.000 description 12
- 210000002767 Hepatic Artery Anatomy 0.000 description 10
- 230000017531 blood circulation Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 238000001356 surgical procedure Methods 0.000 description 9
- 230000037250 Clearance Effects 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 210000003240 Portal Vein Anatomy 0.000 description 6
- 230000035512 clearance Effects 0.000 description 6
- 230000003908 liver function Effects 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 6
- 206010008909 Chronic hepatitis Diseases 0.000 description 5
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 5
- VEQOALNAAJBPNY-UHFFFAOYSA-N Phenazone Chemical compound CN1C(C)=CC(=O)N1C1=CC=CC=C1 VEQOALNAAJBPNY-UHFFFAOYSA-N 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- -1 dimethylaminoethyl Chemical group 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 229960005222 phenazone Drugs 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- SNIOPGDIGTZGOP-UHFFFAOYSA-N 1,2,3-propanetrioltrinitrate Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 4
- 210000001015 Abdomen Anatomy 0.000 description 4
- 210000003975 Mesenteric Arteries Anatomy 0.000 description 4
- 229940014995 Nitroglycerin Drugs 0.000 description 4
- 239000000006 Nitroglycerin Substances 0.000 description 4
- 210000002381 Plasma Anatomy 0.000 description 4
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N Theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 4
- 229960003711 glyceryl trinitrate Drugs 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 101710027066 ALB Proteins 0.000 description 3
- 102100001249 ALB Human genes 0.000 description 3
- 206010003445 Ascites Diseases 0.000 description 3
- 229960001231 Choline Drugs 0.000 description 3
- 210000002989 Hepatic Veins Anatomy 0.000 description 3
- DDBREPKUVSBGFI-UHFFFAOYSA-N Phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 3
- 229960002695 Phenobarbital Drugs 0.000 description 3
- AQHHHDLHHXJYJD-UHFFFAOYSA-N Proprasylyt Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229940050528 albumin Drugs 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- CRBHXDCYXIISFC-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CC[O-] CRBHXDCYXIISFC-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 201000010238 heart disease Diseases 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 238000006213 oxygenation reaction Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000001225 therapeutic Effects 0.000 description 3
- 108010082126 Alanine Transaminase Proteins 0.000 description 2
- 229940091110 Antipyrine Drugs 0.000 description 2
- 210000000941 Bile Anatomy 0.000 description 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 2
- 229940088029 Cardizem Drugs 0.000 description 2
- 102100010966 GPT Human genes 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010019233 Headache Diseases 0.000 description 2
- 208000005176 Hepatitis C Diseases 0.000 description 2
- 206010019755 Hepatitis chronic active Diseases 0.000 description 2
- 210000001630 Jejunum Anatomy 0.000 description 2
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 2
- 210000001758 Mesenteric Veins Anatomy 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N Perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 210000002784 Stomach Anatomy 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 229960000278 Theophylline Drugs 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- 230000000271 cardiovascular Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000001684 chronic Effects 0.000 description 2
- 230000001186 cumulative Effects 0.000 description 2
- 230000002354 daily Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 235000019156 vitamin B Nutrition 0.000 description 2
- 239000011720 vitamin B Substances 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002383 Angina pectoris Diseases 0.000 description 1
- 210000001367 Arteries Anatomy 0.000 description 1
- 229960005261 Aspartic Acid Drugs 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 230000035639 Blood Levels Effects 0.000 description 1
- 240000000218 Cannabis sativa Species 0.000 description 1
- 206010007541 Cardiac disease Diseases 0.000 description 1
- 210000000170 Cell Membrane Anatomy 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 1
- 206010048652 Enzyme induction Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 230000036826 Excretion Effects 0.000 description 1
- 210000001105 Femoral Artery Anatomy 0.000 description 1
- 210000003191 Femoral Vein Anatomy 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 210000004907 Glands Anatomy 0.000 description 1
- 229940096919 Glycogen Drugs 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- BYSGBSNPRWKUQH-UJDJLXLFSA-N Glycogen Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)O1 BYSGBSNPRWKUQH-UJDJLXLFSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 210000000936 Intestines Anatomy 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 229960000448 Lactic acid Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N Malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 210000002464 Muscle, Smooth, Vascular Anatomy 0.000 description 1
- 208000003067 Myocardial Ischemia Diseases 0.000 description 1
- 229940105631 Nembutal Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N Pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 229960001412 Pentobarbital Drugs 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 210000002966 Serum Anatomy 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N Silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- FKHIFSZMMVMEQY-UHFFFAOYSA-N Talc Chemical compound [Mg+2].[O-][Si]([O-])=O FKHIFSZMMVMEQY-UHFFFAOYSA-N 0.000 description 1
- 206010044248 Toxic shock syndrome Diseases 0.000 description 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K Trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 210000001364 Upper Extremity Anatomy 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 210000003462 Veins Anatomy 0.000 description 1
- 229940046001 Vitamin B Complex Drugs 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229940046009 Vitamin E Drugs 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 241001453327 Xanthomonadaceae Species 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 150000008043 acidic salts Chemical class 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000001430 anti-depressive Effects 0.000 description 1
- 230000001754 anti-pyretic Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000003190 augmentative Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- ZEWYCNBZMPELPF-UHFFFAOYSA-J calcium;potassium;sodium;2-hydroxypropanoic acid;sodium;tetrachloride Chemical compound [Na].[Na+].[Cl-].[Cl-].[Cl-].[Cl-].[K+].[Ca+2].CC(O)C(O)=O ZEWYCNBZMPELPF-UHFFFAOYSA-J 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 230000003412 degenerative Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000000916 dilatatory Effects 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960000443 hydrochloric acid Drugs 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 230000001146 hypoxic Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000002452 interceptive Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000002045 lasting Effects 0.000 description 1
- 230000003212 lipotrophic Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002503 metabolic Effects 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L na2so4 Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000001575 pathological Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000003836 peripheral circulation Effects 0.000 description 1
- WRLGYAWRGXKSKG-UHFFFAOYSA-M phenobarbital sodium Chemical compound [Na+].C=1C=CC=CC=1C1(CC)C(=O)NC([O-])=NC1=O WRLGYAWRGXKSKG-UHFFFAOYSA-M 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001187 sodium carbonate Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 101700082413 tant Proteins 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 230000001256 tonic Effects 0.000 description 1
- 230000002936 tranquilizing Effects 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000001052 transient Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 239000011778 trisodium citrate Substances 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003700 vitamin C derivatives Chemical class 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 150000003712 vitamin E derivatives Chemical class 0.000 description 1
- 230000003442 weekly Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
Abstract
The present invention relates to: method for the treatment of liver disease selected from the group consisting of cirrhosis of the liver, toxic liver damage and by drugs, a parenchymal disorder of the liver or hepatitis, said method includes administering to a human or animal with the need thereof, a therapeutically active or prophylactically effective low dose amount of a vasodilating agent, which selectively increased the supply of oxygenated blood to the liver by increasing the hepatic arterial influx. In one aspect of the invention, the effective low dose amount of the vasodilator administered was reduced with increases in the severity of the disease condition being treated.
Description
A METHOD FOR TREATING LIVER DISEASES AND SIMILAR INDICATIONS WITH VASODY-ATTACKING AGENTS
DESCRIPTION OF THE INVENTION
The present invention relates to a method for the treatment of liver disease. The invention also relates to compositions suitable for use in the treatment of liver disease. Diltiazem is a generic name given to the active component of a composition that is primarily used for the treatment of heart disease. Specifically, it is known as 3-acetoxy-5- (2-dimethyl-a-minoethyl) -2,3-dihydro-2- (4-methoxyphenyl) -1,5-benzothiazepine-4) 5H-one. This compound is the active ingredient in the cardiac treatment drug Cardizem. Cardizem has particular efficacy in the treatment of ischemic heart disease including angina pectoris and hypertension. Diltiazem is a member of a broad class of benzothiazepine derivatives which are the subject of Australian patent 426146. The class of compounds is referred to in that specification as having particular utility as an antidepressant, tranquilizers and coronary vasodilators. Diltiazem mainly acts as a calcium channel blocker (a calcium blocker); Calcium being involved in several biological processes in the human body including vasoconstriction and va on to t a t ion. Calcium blockers interfere with the transport of calcium through the cell membrane, thus reducing the contraction of the vascular smooth muscle and causing the arteries to dilate. The discovery of calcium blockers was a major advance in cardiovascular treatment. Diltiazem contributed significantly to this advance. In general, during the cardiovascular trial using Diltiazem, a patient with the need for it is administered the drug in doses of 180 mg to 360 mg per day. The liver is a large gland located in the upper part of the abdomen on the right side. Its domed top surface fits tightly against the lower surface of the right diaphragm. It has a double blood supply from the hepatic artery (oxygenated arterial blood) and the portal vein (substances that carry - deoxygenated venous blood absorbed from the stomach, small intestine and large intestine). It comprises thousands of tiny lobes (liver lobes) the functional units of the liver. Its multiple functions include the storage and filtration of blood, the secretion of bile, the excretion of bilixubine and other substances formed anywhere in the body and numerous metabolic functions, including the conversion of sugars to glycogen, which stores. It is essential for life and therefore the malfunction of the liver weakens and endangers life. The prior art treatments of liver disease have included using a number of drugs. For example, choline has been administered as an adjunct to the dietary treatment of fatty acid infl uction and early cirrhosis of the liver. Methionine has a lipotropic action similar to choline. It has also been used as an aid in the treatment of diseases of the liver in patients who can not take an adequate diet, although it is evident that in cases of severe liver damage large doses of methionine can aggravate the taxoemia. Litrison is a composition of methionine, choline, B vitamins and Vitamin E. It has been used for the treatment of degenerative changes to restore liver function and to maintain liver function. Neurogem is a composition of the essential vitamin B complex of high potency and vitamin C, which has been used for supplement therapy or maintenance. Finally, Ripason is a total protein-free extract from the livers of healthy animals. It has been used to treat chronic hepatitis, cirrhosis, damage to the liver due to medications and upheavals in the liver. The treatment of liver disease, however, has been a growing challenge in the prior art and none of the drugs used has proven to be particularly effective. In particular, none of these agents reverses relative hypoxia, or lack of oxygen, which seems to contribute to the pathology and progression of chronic liver disease. Therefore, liver disease is a life-threatening disease and may eventually require transplant surgery in some cases.
Accordingly, it is an object of the present invention to overcome, or at least alleviate, one or more of the difficulties or deficiencies related to the prior art. Accordingly, in a first aspect of the invention, there is provided a method for the treatment of liver disease and similar indications, said method includes administering to a human or animal with the need thereof a low dose of a therapeutic amount or prophylactically effective of a vasodilator agent, which selectively increases the supply of oxygenated blood to the liver. The vasodilating agent may include a calcium blocker, for example, a thiazepine derivative, preferably a ben z or t i -acidine derivative, nufedipine, felodipine or verapamil. Other vasodilators can be used indirectly. The method of treatment can be used in the treatment of various diseases of the liver such as cirrhosis of the liver, toxic damage to the liver or by drugs or disorders of the liver and related diseases such as hepatitis, including chronic active hepatitis. The treatment method can be directional since significantly lower doses can be used which are usually administered in the treatment of heart disease or similar indications. _ In particular, it has been found that the required dose is reduced with increases in? severity of the condition of the disease being treated. Although not intended to be restricted by theory, it is believed that the class of vasodilated agents known as calcium bleachers are effective in the treatment of liver disease since they are selectively capable of increasing the oxygen content in the liver. In particular, it is believed that calcium blockers are effective in the treatment of liver disease since they are selectively capable of dilating the hepatic artery. An increase in the oxygen level can alleviate the progress of liver disease, since liver function generally increases with an increase in oxygen concentration. Common liver diseases, such as chronic hepatitis or cirrhosis of the liver, share as a pathological aspect a low oxygen concentration in the liver. Accordingly, in a further aspect of the present invention, there is provided a method for the treatment of liver disease, said method includes administering to a human or animal in need thereof a therapeutically or prophylactically effective amount of a derivative of in a cepi na of the formula:
wherein R1 is a phenyl group substituted or not with 1 to 3 lower alkyl groups, lower alkoxy groups or halogen atoms, R2 is a hydrogen atom or a lower alkanoyl group, R and R are each a lower-alkyl group and they may be the same or different, X is a hydrogen atom or a halogen atom, and Y is an alkylene group of 2 or 3 carbon atoms, or its non-toxic acid addition salt. Preferably, R1 is a 4-a1 coxy f1 i or lower, R2 is lower alkanoyl, R3 and R4 are each lower alkyl, X is hydrogen, Y is ethylene. More preferably, R1 is 4-me t-oxy phenyl, R2 is acetyl and R3 and R4 are each methyl. Even more preferably, the benzyl or acetyl derivative is 3-acetoxy-5- (2- (dimethylaminoethyl) -2,3-dihydro-2- (4-methoxyphenyl) -1,5-beniazepine-4) 5H- ona The benzyl derivative may be converted to its acidic salts by addition with treatment with an organic or inorganic acid (eg acetic acid, oxalic acid, malonic acid, tartaric acid, malic acid, citric acid, lactic acid, acid). gluconic acid, aspartic acid, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, perchloric acid, etc.) in a suitable solvent (for example, water, methanol, ethanol, etc.). It has been found that the use of said derivatives of b in z or t i a c ep i na is effective to increase hepatic arterial blood flow to the liver. Said derivatives of b in z or t i a cepri na may be effective in the treatment of liver disease in doses significantly lower than that normally administered in the treatment of cardiac diseases. Significantly lower is meant to imply doses that will not have any significant effect on the heart or peripheral circulation.
In a further preferred aspect of the present invention, there is provided a method for the treatment of liver disease, said method includes administering to a patient with the need thereof a low dose of a vasodilating agent, for example of about 2.5 mg. at 30 mg per day, preferably around 2.5 to 15 mg / day of diltiazem or its non-toxic acid addition salt. Experimental studies in mice have currently indicated effective doses of approximately 1.5 to 2.5 mg / kg / day. However, it is common for doses for humans that are lower than for animals, including rodents. A lower dose may be used for patients with higher degrees of liver disease, the amount of effective low dose of the vasodilator agent being reduced with increases in the severity of the disease state-which is being treated.
Accordingly, in a further aspect of the present invention there is provided a pharmaceutical composition suitable for the treatment of liver disease and indications, if any, said composition includes a therapeutically or prophylactically effective amount of a vasodilating agent, which selectively increases the supply of - oxygenated blood towards the liver and a pharmaceutically acceptable diluent or vehicle of the same. The vasodilating agent may include a calcium blocker, for example a derivative of t-accepine, preferably a derivative of ben z or t i a cepin, nifedipine, felodipine or verapamil. 0 t no vasodilators can be used indirectly. The pharmaceutical composition can be used in the treatment of various liver diseases such as cirrhosis of the liver, toxic liver damage or by drugs or disorders of the liver and related diseases such as hepatitis, including chronic active hepatitis. * In a further preferred aspect of the present invention, there is provided a pharmaceutical composition suitable for the treatment of liver disease and similar indications, said composition includes a therapeutically or prophylactically effective amount of a ben z or thiol derivative of the formula:
wherein R1 is a phenyl group substituted or not with 1 to 3 lower alkyl groups, lower alkoxy groups, or halogen atoms, R2 is a hydrogen atom or a lower alkanoyl group, R3 and R4 are each a lower alkyl group and they may be the same or different, X is a hydrogen atom or a halogen atom and Y is an alkylene group of 2 to 3 carbon atoms, or its non-toxic acid addition salt; and a pharmaceutically acceptable diluent or vehicle thereof.
Preferably, R1 is a 4-a1 coxy f1 i or lower, R2 is lower alkanoyl, R3 and R4 are each lower alkyl, X is hydrogen, Y is ethylene. More preferably, R 1 is 4-me t oxy phenyl 1, R 2 is acetyl and R 3 and R 4 each are methyl. Even more preferably, the benzoyl-a-cepin derivative is 3-acetoxy-5- (2- (dimethylaminoethyl) -2,3-dihydro-2- (4-methoxy-phenyl) -1,5-benzothiazepine-4) 5H-one. In a further preferred aspect of the present invention, a pharmaceutical composition suitable for the treatment of liver disease and similar indications is provided, said composition includes about 2.5 to 30 mg of diltiazem or its non-toxic acid addition salt, and a diluent or pharmaceutically acceptable vehicle thereof. A dose at the low level of the scale can be used in patients with higher degrees of liver disease. The pharmaceutically acceptable diluent or vehicle can be of any suitable type. The pharmaceutically acceptable diluent or carrier can be a suitable organic or inorganic carrier material for enteral, parenteral or transdermal applications.
Preferably, the composition is formulated in order to allow adequate administration to the patient. Said administration can be any suitable medium such as oral, subcutaneous, intravenous or cu r t o s t. Preferably, the administration is via the oral route since the active ingredient is able to reach the liver directly, ie through the portal vein. Oral administration through the use of tablets, capsules, powders or in liquid form such as suspensions, solutions, emulsions or syrups, is particularly advantageous. When formed into tablets, conventional excipients (e.g., sodium citrate, lactose, microcrystalline cellulose, starch, etc.), lubricating agents (e.g., anhydrous silicic acid, hydrolyzed castor oil, magnesium stearate, lauryl) can be used. sodium sulfate, talc, etc.), and binders (eg, starch grass, glucose, lactose, acacia gum, gelatin, mannitol, magnesium trisilicate, talc, etc.). When they are administered as liquids, conventional liquid vehicles can be used. In the case of solid preparations, each unit dose form of the active ingredient may contain from about 5 to about 95% thereof by weight of the total composition the remainder comprising conventional pharmaceutical carriers. When the therapeutic agent is used as an aqueous solution, i.e., injection, the solution may contain from about 0.05 to about 0.5% thereof by weight of the total composition. Preferably, the composition may be of the sustained release type, for example, to allow for "once-a-day administration." The sustained release composition may be suitable for oral or transdermal administration.A suitable low release formulation may be achieved, by example, when the active ingredient is bound to a suitable polymer.A composition once a day is capable of delivering a sufficient amount of the active ingredient to the patient and can avoid the possibility of toxic shock, when multiple doses are given on a daily basis to patients suffering from "liver disease. The present invention will now be described more fully with reference to the appended examples. However, it should be understood that the following description is illustrative only and should not be taken in any way as a restriction of the generality of the invention described hereinabove.
EXAMPLE 1 OBJECTIVE A pilot study was conducted to examine the effect on the hepatic artery and the flow of the mesenteric artery in anesthetized dogs when exposed to cumulative doses of diltiazem.
METHODS: Preparation: Greyhounds were used in this pilot study. All dogs were present in an animal shelter during < 1 week before surgery, and all seemed clinically well. The dogs were given 15 minutes of exercise before arriving at the amphitheater. When they arrived, they were fastened to the abdomen, front legs and hindquarters, and anesthesia was induced with a sodium tonic (Nembutal for T injection) given intravenously to be performed. The subjects were fitted with tubes and connected to a respirator. A heating table was used to maintain body temperature. An initial infusion of one liter of a Hartmann's solution was given through the surgical procedure, bicarbonate being administered as required according to the blood gas estimation. The abdomen was opened, and the ga s t r o-duodena 1 branch of the common hepatic artery was localized and ligated. Electromagnetic flux probes were placed on the common hepatic artery and the anterior mesenteric artery. A branching was exposed to the vein and a catheter was introduced and advanced towards the portal vein. A catheter was also placed in the left hepatic vein using a bag sequence technique. A resident catheter was placed in a branch of the mesenteric vein, very close to the other catheter placed in the lumen of the jejunum. The abdomen was then closed and a catheter was inserted into the femoral artery. The subject was then covered with gauze, and the circulation and temperature of the dogs were allowed to stabilize before the start of the experimental stage.
At the end of the study, the dogs were slaughtered with sodium carbonate.
Experimental procedure: Infused theophylline was used as a marker for liver extraction. A bolus was provided (for 15 minutes) at a rate of 3.42 mg / minute, then an infusion into the mesenteric vein at a rate of 11 mg / minute. After 90 minutes of stabilization, the first dose of diltiazem (0.25 mg / kg) was given in a lumen of the jejunum. Time was allowed for changes in blood flow before the next dose was given. The effects on the flow reached a platform at 2.0 minutes, when the next dose was provided. Cumulative doses were given, that is to say 0.25, 0.5, 1.0, 2.0, 4.0 mg / kg. Blood samples were taken throughout the procedure of the portal vein, posterior hepatic vein and arterial line at 20, 40, 60, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180 and 190 minutes, time zero being the start of the infusion of theophylline.
RESULTS: Studies were conducted in 6 dogs, as follows: Dog Experimental Dog Preparation 3/92 Good surgery No flow response Dog 4/92 Good surgery Excellent flow response to diltiazem Dog 1/93 Good surgery Flow response to diltiazem Dog 2/93 Good surgery Excellent flow response to diltiazem Dog 3/93 Unsuccessful surgery - Dog 4/93 Good surgery Flow response to diltiazem
STATISTICAL OBSERVATIONS Mean flows were obtained in both the hepatic and mesenteric arteries for 10 to 20 minutes before providing dil-tiazem. This was taken as baseline flows, and all the measurements that were used in it were baseline. The maximum flow responses were measured. The results are summarized in the table below and are presented schematically in Figures 1-5.
Common Hepatic Artery Subject +% CHA +% CHA +% CHA +% CHA +% CHA 0.25mg / kg 0.5mg / kg 1.0mg / kg 2.0mg / kg 4.0mg / kg
4/92 t12.4 121.7 123.2 134.0 119.6
1/93 99.9 86.0 71.2 73.2 * 140.7
2/93 151.5 178.7 201.3 227.6 156.0
4/93 104.7 110.1 112.8 112.8 93.5
MEDIA 117.1 + 11.7 124.1 + 19.7 127.1 + 27.2 136.9 + 32.8 127.5 + 13.6
Anterior Mesenteric Artery Subject +% AMA +% AMA +% AMA +% AMA +% AMA 0.25mg / kg 0.5mg / kg 1.Omg / kg 2.0mg / kg 4.0mg / kg
4/92 114.6 112.9 120.9 116.6 118.1 • 1/93 114.9 132.4 177.8 161.5 168.3
2/93 121.1 127.0 129.3 125.1 123.2
4/93 106.7 106.7 103.3 104.1 82.8 MEDIA 114.3 + 3.0 119.8 + 6.0 132.9 + 15.9 126.8 + 12.3 123.1 + 17.5
EXAMPLE 2 Two types of experiments were performed. Both were conducted in dogs anesthetized with barbiturates. In the first series, nitroglycerin was infused into both the portal vein (draining into the liver from the intestine) and the femoral vein (systemic circulation). When nitroglycerin was given in the portal vein, blood flow through the hepatic artery (ie, a measure of liver blood flow and oxygenation) was increased. In contrast, when nitroglycerin was given systematically, the hepatic blood flow was reduced. It can be concluded that liver flux and liver oxygenation can both be augmented by drugs, but this can not be achieved through systemic administration of nitroglycerin. In a second series, diltiazem was administered through a gastric tube to the stomach, effectively and orally. The level of blood flow through the hepatic artery increased by up to 50%, and this occurred at very small doses. In this way, the increase in the perfusion of the liver can be achieved through small doses of oral diltiazem and this will have a benefit in the diseased liver.
EXAMPLE 3 A third group of experiments was then conducted in rats after the first studies in dogs showed that low doses of diltiazem increased the blood flow of the liver. The objective of the study was to induce liver disease through the administration of carbon tetrachloride (CC14) and then test the hypothesis that low doses of diltiazem. They can improve the functional status of the liver.
METHODS Se. used Spregue Dawley male rats in this study, where liver disease was induced after the method of Proctor and Chatamra (1982). First hepatic enzymes were induced through the addition of sodium phenobarbitone to water to drink at a concentration of 350 mg / 100 ml. All animals were provided with phenobarbitone water for 10 weeks. No other type of water was available for the animals. The animals were randomly placed for the induction of liver disease by receiving CCI4 added to corn oil, and administered orally through a stainless steel feeding tube during carbon dioxide stunning. The CCI4 was given for 10 weeks as the weekly doses began after two weeks of enzyme induction with phenobarbitone. The starting dose of. CC14 was Q.5 ml, but the dose was then adjusted according to a protocol to obtain a weight loss of 6 to 9% during the 3 days after each dose, with a weight gain on 'day 7. Previous studies showed that during a period of 10 weeks, this regimen will produce liver disease with ascites, spl enomega 1 a, plasma albumin reduction, plasma alanine transaminase increase, and the isthological aspects of severe liver disease. For the determination of the effects of diltiazem, the animals were separated into 5 groups, each of 8 rats. Group 1 (normal) received phenobarbitone in drinking water but not CCI4 or diltiazem. Group 2 (control) received CCI4 but not diltiazem. Groups 3, 4 and 5 respectively received 0.5, 1.0 and 2.0 mg / kg of diltiazem added to drinking water. The animals were weighed daily for 4 days after each dose of CC14, and were sacrificed after two weeks, ie after 10 weeks of CCI4 +/- diltiazem, or at the equivalent time in normal animals. At autopsy, liver and vessel weights, the presence of ascites and the condition of the coating were recorded, and blood samples were taken to measure albumin, liver enzymes and coagulation factors. The differences between the groups for each variable were examined using analysis of variance.
RESULTS The body weight profiles are shown in Figure X. Group 1 animals (normal) progressively increased the weight of less than 200 g "approximately 440 g of body weight during the study period. ) lost weight after each dose of CC14 and did not gain as much weight as group 1, being 50 to 60 grams lighter at the end of the study period.The treatment with 0.5 mg / kg / day of diltiazem (Group 2) It seemed to have no significant effect to prevent weight loss induced by CCI.4 In contrast, in Group 3 (treated with 1.0 mg / kg / day of diltiazem), there was a transient loss in weight after each dose of CC14. However, at the end of the study, the body weights were not significantly different from the normal (Group 1), but were significantly stronger than those of the control animals (Group 2, p <0.05). 2.0 mg / kg / day (Group 5) seemed less than those of 1.0 mg / kg / day a. Autopsy and biochemical variables are listed in Table Y. In Groups 1 (normal) and 4
(diltiazem, 1.0 mg / kg / day), liver and vessel appeared normal on inspection, and no significant ascites were present. In contrast, Group 2 (control) showed evidence of severe liver disease. The macroscopic changes seen in the control group are supported by the reduction of plasma albumin and coagulation factors and plasma alanine transaminase increase compared to levels in the normal group of animals. Diltiazem offered significant protection against the development of severe functional liver disease and this effect appeared to be greater at a dose of 1.0 mg / kg / day.
DISCUSSION AND CONCLUSION The results of this study in rats show in conclusion that low doses of diltiazem significantly prevented the development of liver disease in rats with the administration of CC14. Particularly important is the observation that the greater effect of diltiazem appeared to be at a dose of 1.0 mg / kg / day instead of 0.5 or 2.0 mg / kg / day. Previous studies in dogs suggest that the mechanism of action is probably found in an increase in blood flow to the liver, and, therefore, improved oxygenation of the liver. These observations in animals should now be tested in human patients with liver disease. The variables that are measured should include determination of liver function, hepatic blood flow, and hepatic vein oxygen tension. Finally, it should be understood that various other modifications and / or alterations may be made without departing from the spirit of the present invention as indicated herein.
EXAMPLE 4 Phase I Clinical Studies of Diltiazem at Low Doses in Patients with Liver Disease Two studies were conducted to test the hypothesis that a low dose of diltiazem may be effective in the management of patients with chronic liver disease. In January 1996, the first study of patients with chronic hepatitis (hepatitis C) was completed and showed a highly significant response in two thirds of patients after only two weeks of treatment. This compares favorably with a regime of. 30% response after 12 weeks of treatment with inferred. The result after diltiazem is even more significant since all the patients were refractory to the treatment with inferieron. A second study in patients with cirrhosis of the liver is being conducted. However, the results in the first two patients indicate that diltiazem administered as 50 mg per day in the 24 hour release formulation is increasing the liver clearance of antipyrin, a marker dye of liver function.
Details of the Study a) Chronic Hepatitis The study of the effects of diltiazem at low doses in chronic hepatitis was performed, in 24 patients with chronic viral hepatitis (hepatitis C) who did not respond to treatment with inferred, and who had stable but high blood levels of the amino t r ans f e r of alanine enzyme in the liver (ALT) and other enzymes. The study was conducted at Alfred Hospital, Melbourne, Australia and was approved by the Ethics Review Committee at that hospital. Each patient who entered the study experienced an operation phase of two weeks followed by four periods, each lasting two weeks. Diltiazem was administered in incremental doses of 12.5, 25, 50 and 100 mg per day in each of the two week periods. The formulation of diltiazem was in Cardicem CD granules reformulated in the respective doses thus giving a low dose, but with a drug release of 24 hours. Blood samples were taken twice for the measurement of ALT in serum and liver enzymes, during the period of operation, and then at the end of each incremental dose period. A final ALT measurement was made two weeks after completing the study. A full report is not yet available until January 1996, but the main results can be summarized as follows. Twenty-four patients introduced to the study, and 19 completed it. Five patients withdrew due to symptoms of hepatitis and social pressure unrelated to diltiazem. The reasons cited included headache and impotence during the placebo operation phase. Four patients had a modest increase in ALT and two had no significant change. Thirteen had a fall in ALT which appeared to be higher after doses of 50 and 100 mg. Six patients had a fall in ALT greater than 20% and this appeared to be greater after a dose of 50 mg, although the response after 25 mg was almost as large. These data approximate one-half of the ALT evaluation after only two weeks of treatment. Table 4 shows the responses in those patients who had a fall in ALT.
Table 4 - Average change in respondents
Upper limit than normal for ALT is 40 lu / ml
Data from patients who experienced more than 20% drop in ALT are shown in Table 5. Table 5 - Mean change in responders Time Dose n Average level of pre ALT 'mean ALT at that time 4 weeks 12.5 170.3 126.7 0.002
6 weeks 25 157.1 104.5 0.003
8 weeks 50 142.1 95.6 0.001
weeks 100 153.1 105.0 0.008 post (average) 7 160.0 106.3 0.003
The total data are consistent with an auxiliary and therapeutic effect, and coincide with the effects * of diltiazem at low doses seen in animals. The study can not show whether a higher response regimen or a greater therapeutic effect can be achieved after longer periods of therapy. However, the results need to be compared with those of the inferred study, a curative therapy, where the response time is reported as 12 weeks. It is also interesting to note that ALT did not appear to increase immediately after the interruption of diltiazem. This is consistent with reoxygenation through dilation of the hepatic artery thus allowing a healing effect, instead of directly interfering with the disease process. There was no evidence that 100 mg was more effective than 50 mg. The increase of enzymes in four patients indicates that the dose of the drug should be kept as low as possible. The patients also reported that they felt better while taking the drug. Several individuals reported less fatigue and headache, and more energy, b) Cirrhosis of the Liver This study is logically difficult to perform and is incomplete. Ten patients with chronic, but stable cirrhosis of the liver were recruited and each received 50 mg of diltiazem formulated from Cardizem-CD pellets for 24-hour release. A clear de-antipyrin study was performed on each patient in the recruitment, after the first dose of treatment and then again for two weeks of treatment. At the same time a possible measurement of propanolol clear could be made. The purpose of antipyretic clearance is to measure liver function in terms of the ability of the liver to excrete substances into bile. The purpose of the propranolol clearing is to measure the capacity of the cytochrome p450 system, which is critical for the oxidation process and the oxidation with the liver. A clear study involves intravenous injection of a dye or marker (in this case, antipyrine or radiolabeled propanolol), followed by repeated blood tests of up to 12 hours. The reduction in the levels of the marker in the blood allows the measurement of the clearance regime of the dye from the body, and in this case by the liver. In January 1996, two patients completed the clear study, and both showed an increase in antipyrin clearance. The first patient increased the antipyrin clearance of 468.2 units before treatment to 494 units after the first dose, and 730.4 units after 2 weeks of t r a tten. This represents a 56% increase in the clearance of antipyrine in a patient with severe disease. The second patient with a more severe disease had a smaller but impor tant increase.
Claims (3)
1. A method for the treatment of liver disease selected from the group that 5 consists of cirrhosis of the liver, damage of the toxic liver and by drugs, parenchymal disorder of the liver or hepatitis, said method includes admiering to a human or animal with the need thereof a therapeutically active low dose or (flfc 10 prophylactically effective on the scale of * 2.5 to 30 mg per day of a vasodilating agent to selectively increase the supply of oxygenated blood to the liver by increasing the arterial blood pressure
2. The method according to claim 1, wherein the vasodilating agent is a calcium blocker.
3. The method according to claim 2, wherein the blocker of. Calcium is a related thiazepine derivative or calcium blocker.
4. The method according to rei indication 2, wherein the calcium blocker is selected from a ben z or t i a cepi na derivative, nifedipine, felodipine or verapamil.
5. The method according to claim 4, wherein the benz or t i a cepin derivative is a compound of the formula: wherein R1 is a phenyl group substituted or not with 1 to 3 lower alkyl groups, lower alkoxy groups or halogen atoms, R2 is a hydrogen atom or a lower alkanoyl group, R3 and R4 each are a lower alkyl group and can be the same or different, X is a hydrogen atom or a halogen atom, and Y is an alkylene group of 2 or 3 carbon atoms, or its non-toxic acid addition salt. "The method according to the rei indication 5, wherein R is 4-lower alkoxyphenyl, R 2 is lower alkanoyl, R 3 and R 4 are each lower alkyl, X is hydrogen, Y is ethylene; more preferably, R 1 is 4-methyl t-phenyl, R 2 is acetyl and R 3 and R 4 are each methyl.
7. The method according to the rei indication 6, wherein the benz or thiazepine derivative is 3-ace t oxy-5 - (2 - (dime ti 1 aminoe ti 1) -2, 3-dihydro-2- (4- methoxyphenyl) -1,5-benzothiazepine-4-5H-one or a non-toxic acid addition salt thereof The method according to claim 1, wherein the treatment is admiered to a human being suffering from liver disease.
9. The method according to claim 1, wherein the vasodilating agent is in the form of a slow release formulation for oral admiration.
10. The method according to any of the preceding indications, wherein the vasodilator agent is admiered through the oral route.
11. A composition for the treatment of liver disease selected from the group consisting of cirrhosis of the liver, toxic liver damage or by drugs, parenchymal liver disorder or hepatitis, said composition includes a therapeutically or prophylactically effective dose amount of an agent vasodilator, which selectively increases the supply of oxygenated blood to the liver by increasing the hepatic arterial influx and a pharmaceutically acceptable carrier thereof, in the form of a sustained release composition for oral admiration.
12. The composition according to claim 11, wherein the vasodilating agent is a calcium blocker.
13. The composition according to claim 12, wherein the calcium blocker is a thiazepine derivative or related calcium blocker.
14. The composition according to the rei indication 13, wherein the thiazepine derivative is selected from a ben z or t i -acidine derivative, difedipine, felodipine or verapamil.
15. The composition according to claim 14, wherein the ben z or thiiphenyl derivative is a compound of the formula wherein R1 is a phenyl group substituted or not with 1 to 3 lower alkyl groups, lower alkoxy groups or halogen atoms, R2 is a hydrogen atom or a lower alkanoyl group, R3 and R4 are each a lower alkyl group and can be the same or different, X is a hydrogen atom or a halogen atom, Y is an alkylene group of 2 or 3 carbon atoms, or its non-toxic acid addition salt.
16. The composition according to claim 15, wherein R1 is a lower 4-alkoxyphenyl, R is lower alkanoyl, R3 and R4 are each lower alkyl, X is hydrogen and Y is ethylene. More preferably R1 is 4-me t-oxy phenyl, R2 is acetyl and R3 and R4 are each methyl
17. The composition according to the rei indication 16, wherein the benzothiazepine derivative is 3 -acetyloxy-5 - (2-dimethyl-1-amino-1-yl) -2,3-dihydro-2- (4-methylphenyl) - 1, 5-benzothiazepine-4) 5H-one or a non-toxic acid addition salt of the same
18. . The composition according to any of the rei indications 11 to 17, wherein the benzothiazepine derivative is present in an amount of about 2.5 to 30 mg.
19. The composition according to any of claims 11 to 17, wherein the benzothiazepine derivative is present in an amount of about 2.5 to 15 mg.
20. The composition according to any of claims 11 to 19, wherein the composition is in the form of a tablet, capsule, powder, suspension, emulsion or syrup.
21. The composition according to any of the rei indications 11 to 19, wherein the composition is in the unit dosage solid form and wherein the vasodilating agent is present in an amount of about 5 to about 95% by weight and the remainder comprising conventional pharmaceutical vehicles.
22. The composition according to any of the rei indications 11 to 19, in the form of an aqueous solution containing about 0.05 to about 0.5% of the vasodilating agent.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08667147 | 1996-06-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA99000074A true MXPA99000074A (en) | 2000-06-05 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5453436A (en) | Treatment of athereosclerosis using, carbazolyl-(4)-oxypropanolamine compounds | |
Morgan et al. | Effects of interstrain renal transplantation on NaCl-induced hypertension in Dahl rats. | |
US20070270459A1 (en) | Overactive bladder treating drug | |
HRP20030348A2 (en) | Compositions and methods for lowering plasma lipoprotein (a) and risk factors of cardiovascular diseases | |
BR112020008128A2 (en) | deferiprone delayed-release tablets and methods for using them | |
AU735980B2 (en) | A method of treating liver disease and like indications with vasodilating agents | |
CA2568436A1 (en) | Combination therapy comprising an adenosine a1 receptor antagonist and an aldosterone inhibitor | |
US6818647B2 (en) | Method and composition for restoring diuretic and renal function | |
JP4609877B2 (en) | Chronic rejection inhibitor | |
JP3872834B2 (en) | Maillard reaction inhibitor | |
Davies et al. | The pro‐drug sulindac may reduce the risk of intestinal damage associated with the use of conventional non‐steroidal anti‐inflammatory drugs | |
US6174917B1 (en) | Method of treating liver disease and like indications with vasodilating agents | |
CA2170289C (en) | A method of treating liver disease and like indications with vasodilating agents | |
US6194466B1 (en) | Use of metformin to counteract weight gain associated with valproate and other psychotropic medications | |
MXPA99000074A (en) | A method for treating liver diseases and similar indications with vasodilated agents | |
AU778129B2 (en) | A method of treating liver disease and like indications with vasodilating agents | |
AU730882B2 (en) | A method of treating liver disease and like indications with vasodilating agents | |
AU7647294A (en) | A method of treating liver disease and like indications with vasodilating agents | |
TW200927092A (en) | New medical use of 3-(2,2,2-trimethylhydrazinium) propionate salts | |
JP2532918B2 (en) | Anti-atherogenic agent containing guanidinobenzoic acid derivative as an active ingredient | |
JPS6358808B2 (en) | ||
JP2002506463A (en) | Adenosine A1 receptor antagonist containing compositions and methods for restoring diuretic and renal function | |
JP4019158B2 (en) | Preventive and therapeutic agent for ulcerative colitis and / or Crohn's disease | |
JP2000191535A (en) | Medicine for disease caused by the growth of blood vessel smooth muscle cell | |
JPS59134722A (en) | Preventive and remedy for hemorrhagic infarction |